InMed Pharmaceuticals Inc. (C:IN*CA)

Business Focus: Bio Therapeutic Drugs

Feb 14, 2019 08:02 ET
Edison issues update on InMed Pharmaceuticals (IN)
InMed (IN) recently reported results for the second quarter of FY19 and is on track to bring INM-750 for epidermolysis bullosa (EB) into the clinic by the end of the year. The company recently completed two topical seven-day dose-ranging studies in...
Nov 21, 2018 04:26 ET
Edison issues update on InMed Pharmaceuticals (IN)
InMed recently reported results for the first quarter of FY19 and continues to make solid progress in bringing INM-750 for epidermolysis bullosa (EB) into the clinic by H219. So far, its selected formulation has demonstrated good drug penetration...
Nov 01, 2018 06:00 ET
BTV Explores Tech Companies on Investors' Radar
Vancouver, British Columbia--(Newsfile Corp. - November 1, 2018) - On BNN Sat Nov. 3 & Sun Nov. 4, 2018 - BTV- Business Television visits state-of-the-art technology companies ranging from social media to pharmaceuticals. Full Episode
Sep 25, 2018 07:25 ET
InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
VANCOUVER, Sept. 25, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has filed a Patent Cooperation Treaty ("PCT") application pertaining to the Company's INM-405 program and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which is an important step in protecting the Company's in
Sep 25, 2018 07:25 ET
InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
VANCOUVER, Sept. 25, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has filed a Patent Cooperation Treaty ("PCT") application pertaining to the Company's INM-405 program and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which is an important step in protecting the Compa...
Sep 13, 2018 07:25 ET
InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update
VANCOUVER, Sept. 13, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18").
Sep 13, 2018 07:25 ET
InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update
VANCOUVER, Sept. 13, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18")....
Sep 11, 2018 07:25 ET
InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
VANCOUVER, Sept. 11, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that the Company's research partner, University of British Columbia ("UBC"), has been approved to receive a grant from the Natural Sciences and Engineering Research Council of Canada ("NSERC") for their collaborative efforts with InMed in the biosynthe
Sep 11, 2018 07:25 ET
InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
VANCOUVER, Sept. 11, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that the Company's research partner, University of British Columbia ("UBC"), has been approved to receive a grant from the Natural Sciences and Engineering Research Council of Canada ("NSERC") for their collaborative efforts with InMed in the bi...
Sep 07, 2018 07:25 ET
InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018
VANCOUVER, Sept. 7, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will report financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18"), on Thursday, September 13, 2018.
Sep 07, 2018 07:25 ET
InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018
VANCOUVER, Sept. 7, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will report financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18"), on Thursday, September 13, 2018....
Aug 01, 2018 07:25 ET
InMed to Present at the Canaccord Genuity 38th Annual Growth Conference
VANCOUVER, Aug. 1, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the Canaccord Genuity 38th Annual Growth Conference on August 8th, 2018, at 8:30 AM EST at the InterContinental Boston.
Aug 01, 2018 07:25 ET
InMed to Present at the Canaccord Genuity 38th Annual Growth Conference
VANCOUVER, Aug. 1, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the Canaccord Genuity 38th Annual Growth Conference on August 8th, 2018, at 8:30 AM EST at the InterContinental Boston....
Jun 21, 2018 11:13 ET
InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter's Over-Allotment Option
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jun 12, 2018 09:54 ET
InMed Pharmaceuticals announces increase in Bought Deal offering to $13 million
InMed Pharmaceuticals Inc. (TSX:IN) (“InMed” or the “Company”) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, under which Eight Capital has now agreed to purchase, as underwriter, 14,444,560...
Jun 12, 2018 07:30 ET
InMed Pharmaceuticals Announces $10 Million Bought Deal
InMed Pharmaceuticals Inc. (TSX:IN) (“InMed” or the “Company”) is pleased to announce that it has entered into a letter of engagement with Eight Capital, as underwriter, under which Eight Capital has agreed to purchase 11,111,200 units of the...
May 29, 2018 07:25 ET
InMed to Present at the 8th Annual LD Micro Invitational Conference
VANCOUVER, May 29, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the 8th annual LD Micro Invitational conference on June 4th, 2018, at 2:00 PM PST at the Luxe Sunset Bel Air in Los Angeles, California. 
May 29, 2018 07:25 ET
InMed to Present at the 8th Annual LD Micro Invitational Conference
VANCOUVER, May 29, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the 8th annual LD Micro Invitational conference on June 4th, 2018, at 2:00 PM PST at the Luxe Sunset Bel Air in Los Angeles, California.  ...
May 14, 2018 07:25 ET
InMed Files Patent Application for INM-085 Glaucoma Program
VANCOUVER, May 14, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced it has filed a Patent Cooperation Treaty ("PCT") application for INM-085 as a cannabinoid-based topical therapy for glaucoma, which includes protection of its technology in about 150 different countries including the United States, and claims a priority
May 14, 2018 07:25 ET
InMed Files Patent Application for INM-085 Glaucoma Program
VANCOUVER, May 14, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced it has filed a Patent Cooperation Treaty ("PCT") application for INM-085 as a cannabinoid-based topical therapy for glaucoma, which includes protection of its technology in about 150 different countries including the United States, and claims a pr...
May 11, 2018 07:25 ET
InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update
VANCOUVER, May 11, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2018, which is the Company's third quarter of fiscal year 2018 ("3Q18").
May 11, 2018 07:25 ET
InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update
VANCOUVER, May 11, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2018, which is the Company's third quarter of fiscal year 2018 ("3Q18")....
May 04, 2018 08:30 ET
OTC Markets Group Welcomes InMed Pharmaceuticals Inc. to OTCQX
NEW YORK, May 4, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced InMed Pharmaceuticals Inc. (TSX: IN; OTCQX: IMLFF), a cannabinoid-focused biopharmaceutical company, has qualified to trade on the OTCQX® Best Market.  InMed Pharmaceuticals upgraded to OTCQX from the OTCQB® Venture Market....
May 01, 2018 08:30 ET
Apr 17, 2018 10:31 ET
InMed Pharmaceuticals Inc. Opens the Market
TORONTO, April 17, 2018 /CNW/ - Eric Adams, President & CEO, InMed Pharmaceuticals Inc. (IN), joined Shaun McIver, Chief Client Officer, TMX Group, to open the market. InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed Pharmaceuticals Inc. commenced trading on Toronto Stock Exchange on March 26, 2018.
Apr 17, 2018 08:00 ET
InMed Rings the Opening Bell at the Toronto Stock Exchange
VANCOUVER, April 17, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQB:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced that the Company will ring the opening bell at the Toronto Stock Exchange ("TSX") today in honor of its migration to the exchange on March 26, 2018.
Apr 17, 2018 08:00 ET
InMed Rings the Opening Bell at the Toronto Stock Exchange
VANCOUVER, April 17, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQB:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced that the Company will ring the opening bell at the Toronto Stock Exchange ("TSX") today in honor of its migration to the exchange on March 26, 2018....
Apr 11, 2018 08:00 ET
Mar 23, 2018 06:00 ET
InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange
Trading on the TSX will commence March 26, 2018
Mar 23, 2018 06:00 ET
InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange
Trading on the TSX will commence March 26, 2018...
Mar 12, 2018 07:30 ET
InMed to Present at 30th Annual ROTH Capital Conference
VANCOUVER, March 12, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today that Eric A. Adams, CEO & President, will be presenting to U.S. institutional investors at the 30th Annual ROTH Conference, which is being held March 11-14, 2018, at the Ritz Carlton, Laguna Niguel, California.  InMed's prese
Mar 12, 2018 07:30 ET
InMed to Present at 30th Annual ROTH Capital Conference
VANCOUVER, March 12, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today that Eric A. Adams, CEO & President, will be presenting to U.S. institutional investors at the 30th Annual ROTH Conference, which is being held March 11-14, 2018, at the Ritz Carlton, Laguna Niguel, California.  InMed'...
Mar 06, 2018 03:30 ET
InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research
Publication on a Novel Hydrogel Formulation for the Treatment of Glaucoma Helps Validate InMed's Fully Integrated, Cannabinoid-based Business Model
Mar 06, 2018 03:30 ET
InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research
Publication on a Novel Hydrogel Formulation for the Treatment of Glaucoma Helps Validate InMed's Fully Integrated, Cannabinoid-based Business Model ...
Jan 04, 2018 11:29 ET
IIROC Trade Resumption - IN
VANCOUVER, Jan. 4, 2018 /CNW/ - Trading resumes in:
Jan 04, 2018 11:28 ET
IIROC Trading Halt - IN
VANCOUVER, Jan. 4, 2018 /CNW/ - The following issues have been halted by IIROC:
Jan 04, 2018 09:08 ET
IIROC Trade Resumption - IN
VANCOUVER, Jan. 4, 2018 /CNW/ - Trading resumes in:
Jan 04, 2018 09:04 ET
IIROC Trading Halt - IN
VANCOUVER, Jan. 4, 2018 /CNW/ - The following issues have been halted by IIROC:
Jan 04, 2018 05:00 ET
InMed Closes Over-Subscribed C$9.4 Million Financing
/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES/
Dec 22, 2017 08:30 ET
CannabisNewsWire Announces Publication on Increased Investment Activity in Cannabis
New York, New York--(Newsfile Corp. - December 22, 2017) - CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of CNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 21, 2017 08:30 ET
CannabisNewsWire Announces Publication Discussing Biotech's Leading Role in the Cannabis Industry
New York, New York--(Newsfile Corp. - December 21, 2017) - CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of CNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 20, 2017 10:17 ET
IIROC Trade Resumption - IN
VANCOUVER, Dec. 20, 2017 /CNW/ - Trading resumes in:
Dec 20, 2017 08:46 ET
IIROC Trading Halt - IN
VANCOUVER, Dec. 20, 2017 /CNW/ - The following issues have been halted by IIROC:
Dec 18, 2017 16:15 ET
Dec 18, 2017 08:30 ET
NetworkNewsWire Announces Publication on the Value of Cannabinoid-based Alternatives to Opioids
New York, New York--(Newsfile Corp. - December 18, 2017) - NetworkNewsWire - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 18, 2017 07:00 ET
Horizons ETFs Expands the Portfolio of its Marijuana-Focused ETF
Upon quarterly rebalance, 11 stocks were added to the HMMJ portfolio
Dec 14, 2017 08:30 ET
NetworkNewsWire Announces Publication Discussing Advances in Cannabinoid-Based Therapies
New York, New York--(Newsfile Corp. - December 14, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 14, 2017 08:30 ET
NetworkNewsWire Announces Publication Discussing the Potential of Cannabinoid-Based Pain Therapies
NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- via NetworkNewsWire - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a client of NNW and...
Dec 13, 2017 08:30 ET
NetworkNewsWire Announces Publication Discussing the Production of Quality Cannabinoids with Therapeutic Potential
NEW YORK, Dec. 13, 2017 (GLOBE NEWSWIRE) -- via NetworkNewsWire - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a client of NNW and...
Dec 11, 2017 08:30 ET
NetworkNewsWire Announces Publication Discussing Advances in Cannabinoids for use in Pain Management
New York, New York--(Newsfile Corp. - December 11, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 08, 2017 07:30 ET
UPDATE - NetworkNewsWire Announces Publication featuring Advances in Cannabinoid Products and Therapies for Pain Management
NEW YORK, Dec. 08, 2017 (GLOBE NEWSWIRE) -- NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a preclinical stage biopharmaceutical company specializing in the research...
Dec 07, 2017 08:30 ET
NetworkNewsWire Announces Publication Discussing Advances in the Manufacture of Cannabinoid Compounds for Medical Purposes
New York, New York--(Newsfile Corp. - December 7, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 07, 2017 08:30 ET
NetworkNewsWire Announces Publication on the Use of Cannabinoids for Pain Management and other Medical Applications  
NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- via NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a preclinical stage biopharmaceutical company specializing in the research...
Nov 17, 2017 08:30 ET
NetworkNewsWire Announces Publication on Innovative Research Being Developed on Cannabinoid-Based Therapies, Drugs
New York, New York--(Newsfile Corp. - November 17, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Nov 16, 2017 08:30 ET
NetworkNewsWire Announces Publication Discussing Biotech Advances in Cannabis Research
New York, New York--(Newsfile Corp. - November 16, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Nov 16, 2017 07:00 ET
Nov 16, 2017 07:00 ET
Nov 09, 2017 08:30 ET
NetworkNewsWire Announces Publication Discussing M&A Activity Driven by the Convergence of Cannabis and Medicine
New York, New York--(Newsfile Corp. - November 9, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
Nov 06, 2017 09:00 ET
CFN Media Exclusive CEO Interview: InMed Pharmaceuticals' Biosynthesis Platform Results in an Industry First
CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an exclusive video interview with Eric A. Adams, CEO of InMed Pharmaceuticals Inc. (CSE: IN)(CSE: IN.CN)(CNSX: IN)(OTCQB: IMLFF). In this interview, CEO Eric A. Adams talks about the company's recent breakthrough, a study in which the team was able to identify a cannabinoid drug candidate for the treatment of glaucoma; biosynthesize that cannabinoid; develop a proprietary hydrogel delivery system; and effectively apply the new drug to the eye in a positive
Nov 06, 2017 09:00 ET
CFN Media Exclusive CEO Interview: InMed Pharmaceuticals' Biosynthesis Platform Results in an Industry First
Seattle, Washington--(Newsfile Corp. - November 6, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an exclusive video interview with Eric A. Adams, CEO of InMed Pharmaceuticals Inc. (CSE: IN) (CNSX: IN) (OTCQB: IMLFF). In this interview, CEO Eric A. Adams talks about the company's recent breakthrough, a study in which the team was able to identify a cannabinoid drug candidate for the treatment of glaucoma; biosynthesize that cannabinoid; develop a proprietary hydrogel delivery system; and effectively apply the new drug to the eye in a positive preclinical study.
Nov 02, 2017 08:30 ET
NetworkNewsWire Announces Publication Discussing Innovative Extraction Methods Used in the Production of Cannabinoids
New York, New York--(Newsfile Corp. - November 2, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
Oct 30, 2017 08:30 ET
NetworkNewsWire Announces Publication Discussing Unique R&D in the Medicinal Marijuana Industry
New York, New York--(Newsfile Corp. - October 30, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
Oct 30, 2017 08:30 ET
NetworkNewsWire Announces Publication Highlighting Advances in CBD Development
New York, New York--(Newsfile Corp. - October 30, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
Oct 26, 2017 08:30 ET
NetworkNewsWire Announces Publication on Biosynthesis for Medicinal-Grade Cannabinoids
New York, New York--(Newsfile Corp. - October 26, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
Oct 24, 2017 06:00 ET
InMed Announces Positive Pre-Clinical Data on an Ocular Hydrogel Formulation using a Biosynthesized Cannabinoid
VANCOUVER, Oct. 24, 2017 /CNW/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today results from a study co-sponsored by InMed (Dr. Sazzad Hossain, Chief Scientific Officer) and the University of British Columbia (laboratories of Profs. Ujendra Kumar and Vikramaditya Yadav).
Oct 24, 2017 06:00 ET
InMed Announces Positive Pre-Clinical Data on an Ocular Hydrogel Formulation using a Biosynthesized Cannabinoid
VANCOUVER, Oct. 24, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today results from a study co-sponsored by InMed (Dr. Sazzad Hossain, Chief Scientific Officer) and the University of British Columbia (laboratories of Profs. Ujendra Kumar and Vikramaditya Yadav). ...
Oct 17, 2017 07:00 ET
InMed Updates Pain Program
CSE: INOTCQB: IMLFF
Oct 17, 2017 07:00 ET
InMed Updates Pain Program
CSE: INOTCQB: IMLFF...
Oct 10, 2017 07:00 ET
Oct 10, 2017 07:00 ET
Oct 03, 2017 07:00 ET
Oct 03, 2017 07:00 ET
Oct 03, 2017 06:00 ET
NetworkNewsWire Announces Publication that Highlights the Limitless Potential of Innovative Drug Development
New York, New York--(Newsfile Corp. - October 3, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
Sep 21, 2017 06:00 ET
InMed Pharmaceuticals Added to CSE25 Index
VANCOUVER, Sept. 21, 2017 /CNW/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce that InMed has been included in the CSE25 Index. InMed qualified for the index as one of the twenty-five largest companies in the CSE Composite Index.
Sep 21, 2017 06:00 ET
InMed Pharmaceuticals Added to CSE25 Index
VANCOUVER, Sept. 21, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce that InMed has been included in the CSE25 Index. InMed qualified for the index as one of the twenty-five largest companies in the CSE Composite Index. ...
Sep 20, 2017 08:30 ET
InMed Pharma: A Leader in Cannabinoid Biosynthesis -- CFN Media
CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering how InMed Pharmaceuticals Inc. (CSE: IN) (CNSX: IN) (IN.CN) (OTCQB: IMLFF) is leveraging biosynthesis to solve a major problem in the medical cannabis industry as it adds key ex-Eli Lilly personnel to its efforts.
Sep 19, 2017 06:00 ET
Sep 19, 2017 06:00 ET
Sep 12, 2017 06:00 ET
Sep 12, 2017 06:00 ET
Sep 07, 2017 09:00 ET
Biosynthesis Could Reduce Regulatory Hurdles for Cannabis Researchers -- CFN Media
CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article examining InMed Pharmaceuticals' (CSE: IN) (CNSX: IN) (IN.CN) (OTCQB: IMLFF) biosynthesis program and how it could address many vexing issues with cannabis drug development.
Aug 18, 2017 09:00 ET
Jul 27, 2017 09:00 ET
Jul 27, 2017 09:00 ET
Jul 13, 2017 09:00 ET
InMed Pharma Advances Cannabinoid EB Therapy -- CFN Media
CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, today announced the publication of an article covering InMed Pharmaceuticals Inc.'s (OTCQB: IMLFF) (CNSX: IN) new research and development deal with ATERA SAS of France and the company's development of INM-750 for the treatment of epidermolysis bullosa (EB).
Jul 10, 2017 08:00 ET
Jul 10, 2017 08:00 ET
InMed Signs R&D Agreement with ATERA
CSE: IN OTCQB: IMLFF...
Jun 14, 2017 09:00 ET
InMed Pharma Advances Toward Clinical Trials with CRO Deal -- CFN Media
CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing InMed Pharmaceuticals Inc. (CNSX: IN) (OTCQB: IMLFF) and the progress it is making in advancing its lead clinical trial candidate.
Jun 13, 2017 09:00 ET
May 31, 2017 11:31 ET
InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
May 24, 2017 14:16 ET
IIROC Trade Resumption - IN
VANCOUVER, May 24, 2017 /CNW/ - Trading resumes in:
May 24, 2017 09:44 ET
IIROC Trading Halt - IN
TORONTO, May 24, 2017 /CNW/ - The following issues have been halted by IIROC:
May 23, 2017 18:19 ET
IIROC Trade Resumption - IN
VANCOUVER, May 23, 2017 /CNW/ - Trading resumes in:
May 23, 2017 17:38 ET
InMed Announces Pricing of $5,004,000 Underwritten Financing
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
May 23, 2017 16:44 ET
IIROC Trading Halt - IN
TORONTO, May 23, 2017 /CNW/ - The following issues have been halted by IIROC:
Feb 27, 2017 06:00 ET
Feb 27, 2017 06:00 ET
Jan 19, 2017 09:00 ET
InMed Pharma Appoints Eli Lilly Finance Executive to Board of Directors -- CFN Media
CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing InMed Pharmaceuticals Inc.'s (OTCQB: IMLFF) (CNSX: IN) recent appointment of Martin Bott to its Board of Directors, the company's existing team, and what it means as InMed progresses towards its first clinical trial in INM-750 for the treatment of Epidermolysis Bullosa as well as the rest of its clinical pipeline.
Jan 18, 2017 09:00 ET
InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,500,000
/NOT FOR DISTRIBUTION TO U.S NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jan 13, 2017 16:36 ET
Jan 13, 2017 16:36 ET
Dec 23, 2016 06:00 ET
InMed Provides 2016 Year End Update
VANCOUVER, Dec. 23, 2016 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, today announced a year end review for 2016.
Dec 23, 2016 06:00 ET
InMed Provides 2016 Year End Update
VANCOUVER, Dec. 23, 2016 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, today announced a year end review for 2016....
Dec 15, 2016 05:00 ET
InMed Pharmaceuticals Announces Appointment of Veteran Biotech CFO, Jeff Charpentier
VANCOUVER, Dec. 15, 2016 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Jeff Charpentier, CPA, CA as InMed's Chief Financial Officer & Corporate Secretary.  
Dec 15, 2016 05:00 ET
InMed Pharmaceuticals Announces Appointment of Veteran Biotech CFO, Jeff Charpentier
VANCOUVER, Dec. 15, 2016 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Jeff Charpentier, CPA, CA as InMed's Chief Financial Officer & Corporate Secretary.   ...
Dec 06, 2016 06:00 ET
InMed announces progress on COPD program
VANCOUVER, Dec. 6, 2016 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), announced progress today on its R&D program in the use of cannabinoids for the treatment of chronic obstructive pulmonary disease (COPD). In June, 2015 InMed initiated its COPD program using its bioinformatics analysis tool to identify the targets and potential active compounds that can be useful for the treatment of COPD. Subsequently, with in vitro assays using human lung fibroblasts (HFL-1 cell line), InMed has demonstrated that certain cannabinoid compounds are capable of affecting a...
Sep 13, 2016 06:00 ET
Jun 16, 2016 09:02 ET
InMed Announces Appointment of Eric A. Adams as CEO, President and Director
InMed Pharmaceuticals Inc. ("InMed" or "the Company") (CSE:IN)(OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies, is pleased to announce today the appointment of Mr. Eric A....
Jun 16, 2016 09:02 ET
InMed Announces Appointment of Eric A. Adams as CEO, President and Director
InMed Pharmaceuticals Inc. ("InMed" or "the Company") (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies, is pleased to announce today the appointment of Mr. Eric A. Adams as CEO, President and as a member of the Board of Directors. Mr. Adams is a seasoned biopharmaceutical executive with over 25 years' experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance.